The first FDA-approved drug for both noise anxiety and separation distress in dogs

Doges Editorial · 2026-05-10 · 5 min read

A new prescription medication called Tessie has become the first drug approved for both noise aversion and separation anxiety at once — addressing a frustrating gap in how anxious dogs have been treated for years.

The thunder comes before the rain, which means your dog knows before you do. By the time the first drop hits, some dogs are already panting under the bed, nails clattering on the hardwood, unable to settle, unable to understand why the sky has turned hostile. For others, it's not the weather at all. It's the jingle of keys. The sound of a coat being pulled from the hook by the door.

Noise aversion and separation anxiety are two of the most commonly reported behavioral conditions in dogs — and they are not the same, though they often share a body. A dog who shakes through every fireworks show and a dog who dismantles the living room during a workday may seem like different problems. Often, they are the same dog.

On May 6, 2026, the FDA changed how veterinarians can approach both at once. The U.S. Food and Drug Administration approved Tessie (tasipimidine oral solution) as the first product to receive federal clearance for both noise aversion and separation anxiety in dogs simultaneously — a distinction that sounds administrative but carries real consequences for how these cases are managed. Medications had previously been approved for each condition separately. No single product had cleared the bar for both until now.

Two fears that travel together

The comorbidity between these two conditions is well-documented but often undertreated. A dog who panics when left alone is frequently also a dog who bolts at fireworks. Both are fear-based responses rooted in the same underlying anxiety — a nervous system that reads the world as more threatening than it is, and responds accordingly. When they appear together, they can amplify each other.

It's not uncommon to see dogs who struggle with some degree of separation anxiety or separation distress also struggle with noise aversion.

— Christopher Pachel, DVM, DACVB, CABC, veterinary behaviorist

Pachel, who runs the Animal Behavior Clinic in Portland, Oregon, says the overlap creates one of the more frustrating dynamics in treating anxious dogs. When two fear systems interact, a single unresolved incident — a thunderstorm during the workday, for example — can undo weeks of careful behavioral progress in one afternoon.

How Tessie works

Tasipimidine, the active ingredient in Tessie, belongs to a class of drugs called alpha-2 adrenoceptor agonists. It works by activating specific receptors in the brain to reduce the heightened fight-or-flight activity associated with fear. It doesn't sedate a dog into stillness — it quiets the neurological alarm that transforms a sound, or an absence, into something intolerable.

The drug is administered orally about one hour before a predictable triggering event: a forecast thunderstorm, a holiday fireworks display, a scheduled owner departure. It can be dosed up to three times within a 24-hour period, with at least three hours between doses. It should not be given with a full meal — though a small treat to help the dog swallow the solution is fine. Tessie is available by prescription, meaning veterinary diagnosis and oversight are required.

What the clinical trials showed

The FDA's approval rested on data from two controlled field studies in client-owned dogs: 160 enrolled in the noise aversion trial, 224 in the separation anxiety study. Both demonstrated that tasipimidine reduced fear-related behavior compared with vehicle controls. The most commonly reported side effects were vomiting and lethargy; diarrhea was also noted in the separation anxiety group.

Laboratory safety studies in beagles showed dose-dependent sedation effects at higher doses — decreased activity, ataxia, changes in heart rate — that were generally reversible between dosing periods. The drug is manufactured by Orion Corporation, a Finnish pharmaceutical company, and is available as an oral solution administered via syringe.

The comorbidity trap

Managing two separate anxiety diagnoses with two separate medications is more complicated than it sounds. Each drug carries its own dosing window, its own side-effect profile, its own requirement for veterinary monitoring. In practice, the dual burden sometimes led owners to prioritize one condition and leave the other inadequately treated — or to stop treatment for both when the logistics became too much.

Noise aversion and separation anxiety together also create what behavioral specialists call trigger stacking — a pattern in which successive unresolved fear events progressively lower the dog's tolerance threshold. A thunderstorm on Tuesday, an owner absence on Wednesday, fireworks on Friday: each compounds the last, leaving the dog incrementally less capable of handling each new challenge.

Knowing that we've got something that is providing therapeutic benefit for both of those conditions simultaneously will hopefully decrease some of that risk of recurrence or regression.

— Christopher Pachel, DVM, DACVB, CABC

Where medication fits

Behavioral modification remains the foundation of care for both conditions. Desensitization to sound triggers, counter-conditioning routines, establishing secure retreat spaces within the home — none of that disappears because a new medication is available. What medication can do, particularly at the beginning of a treatment plan, is provide enough neurological breathing room for those interventions to actually take hold. A dog who is too frightened to learn cannot be trained out of that fear.

If your dog hides during storms, vocalizes when left alone, or destroys objects near exit points, that's the starting point for a conversation with your veterinarian. The presentation matters — the two conditions can look different and may require different emphasis in any treatment plan — and a clearer picture of severity and frequency will help guide the approach.

A different version of the same sound

Tessie joins a veterinary behavioral pharmacopeia that already includes fluoxetine and trazodone, among other options. What makes the new approval distinct is the dual labeling — and what it signals about how the field is evolving. Fear-based behavioral conditions in dogs have historically been underdiscussed, normalized as personality rather than treated as medical issues. A single FDA-approved product that addresses both fronts at once marks a meaningful step.

The next thunderstorm will still come. The owner will still have to leave for work in the morning. But for dogs who have lived with both conditions without adequate treatment, there may now be a path toward making those moments smaller. Not silent — just smaller. A different relationship with the same sound.